The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD),

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression.

FDA approves Spravato as the first monotherapy for adults with major depressive disorder unresponsive to two oral antidepressants. In clinical trials, 22.5% of Spravato patients achieved remission at week 4 vs. 7.6% with placebo. The approval makes the ...

Spravato is the first and only approved monotherapy for adults with refractory major depressive disorder. Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, multicenter, placebo-controlled ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants.

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least 2 oral antidepressants, according to a news release issued by Johnson & Johnson.